therapies & services > GAMMAGARD S/D

GAMMAGARD S/D is a highly effective and purified therapy for immune compromised patients. GAMMAGARD S/D is indicated for use in patients with:

• Primary immune deficiency diseases (PI)
• B-cell chronic lymphoctic leukemia (CLL)
• Idiopathic thrombocytopenic purpura (ITP)
• Kawasaki syndrome

GAMMAGARD S/D is indicated for the treatment of primary immunodeficient states, such as: congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

GAMMAGARD S/D is not indicated in patients with selective IgA deficiency where the IgA deficiency is the only abnormality of concern. See Warnings section of full Prescribing Information for important safety information.

Learn more about PI and GAMMAGARD S/D with these comprehensive brochures.

Information for Healthcare Professionals
Information for Patients

Please see Important Safety Information and Full Prescribing Information for GAMMAGARD S/D [Immune Globulin Intravenous (Human)]

To view PDFs, you will need Adobe® Acrobat® Reader® software.